Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 54 Stomach Neoplasms 42 Carcinoma, Non-Small-Cell Lung 31 Colorectal Neoplasms 21 Esophageal Squamous Cell Carcinoma 15 Nasopharyngeal Carcinoma 11 Lung Neoplasms 11 Rectal Neoplasms 10 Esophageal Neoplasms 9 Pancreatic Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 6 Small Cell Lung Carcinoma 5 Neoplasms 5 Liver Neoplasms 5 Cholangiocarcinoma 5 Uterine Cervical Neoplasms 4 Triple Negative Breast Neoplasms 4 Recurrence 4 Neoplasm Metastasis 4 Carcinoma, Renal Cell 4 Lymphoma, Extranodal NK-T-Cell 3 Colorectal Cancer Metastatic 3 Colonic Neoplasms 3 Carcinoma 3 Breast Neoplasms 3 Turcot syndrome 2 Thyroid Neoplasms 2 Spinocerebellar Degenerations 2 Sarcoma 2 Nonsquamous Non-Small Cell Lung Cancer 2

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumor × sintilimab × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡